Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes.
Alessio Mosca, Stefania Chiappini, Andrea Miuli, Clara Cavallotto, Mauro Pettorruso, Giovanni Martinotti, Fabrizio Schifano
Brain Sci September 17, 2025 DOI: 10.3390/brainsci15091006 via PubMed Central
Summary
Synthetic cannabinoids can cause psychosis that is often severe and difficult to treat. This systematic review examined published case reports and case series to identify effective treatment strategies. The review found that benzodiazepines and antipsychotics are commonly used, but many patients require intensive care and prolonged hospitalization. No single treatment protocol emerged as clearly superior, and outcomes varied widely, with some patients recovering fully while others experienced persistent psychotic symptoms. The authors suggest that early recognition and aggressive management may improve outcomes, but more research is needed to establish standardized treatment guidelines.
Study at a glance
| Characteristics | Systematic review Peer reviewed |
|---|---|
| Citations | 1 |
| Key finding | Benzodiazepines and antipsychotics are commonly used to treat synthetic-cannabinoid-induced psychosis, but no single treatment protocol is clearly superior and outcomes vary widely. |
Abstract
Clinical Management of Synthetic-Cannabinoid-Induced Psychosis: A Systematic Review of Treatment Strategies and Outcomes.